VenaFlux Solutions | wearecellix

rJararacin, a recombinant disintegrin from Bothrops jararaca venom: Exploring its effects on hemostasis and thrombosis - David et al., 2023.

secondary structure of jararacin and its effects on hemostasis and thrombosis | Platelet adhesion under flow | In vitro thrombogenesis

How to conduct a Thrombosis Assay using Cellix's VenaFlux Basic setup with ExiGo pump

VenaFlux Solutions mimic human blood vessels | conduct a Thrombosis Assay | automated high-throughput flow assay system

Lack of transporter-like protein SLC44A2 causes hearing impairment and a rare red blood phenotype

The presence or absence of specific antigens at the red blood cell surface determines blood phenotypes.

Answers to your questions about the VenaFlux Solutions : Frequently Asked Questions (FAQs)

VenaFlux Solutions offers a range of packages to fit different budgets, empowering researchers with innovative tools

The rate of platelet activation determines thrombus size and structure at arterial shear

Antiplatelet therapy reduces stroke and heart attack recurrence risk, but thrombotic diseases remain a leading cause of death

EMT status of circulating breast cancer cells and impact of fluidic shear stress – By Jin et al., 20

Tumour metastasis is a major cause of cancer death, but scientists still don’t fully understand its mechanisms.

New insights into prothrombotic state of post-COVID syndrome patients

Post-COVID Syndrome (PCS) involves long-lasting, unexplained symptoms after SARS-CoV-2 infection, impacting quality of life.

Cardiovascular: Stents; Drug Eluting Stents; Platelet Adhesion

Assess the ability of xemilofiban released in conjunction with fluvastatin, to prevent thrombus formation/platelet adhesion to fibrinogen

Chronic platelet activation contributes to Alzheimers Disease and its progression

Thrombus Formation Assay Under Physiological Flow | ExiGo pump to create physiological flow conditions ranging from 200 to 1000 sec⁻¹